Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes

WB4101 (1)-related compounds 5-10 were synthesized, and their biological profile at alpha(1)-adrenoreceptor (AR) subtypes and 5-HT(1A) serotoninergic receptors was assessed by binding assays in Chinese hamster ovary and HeLa cell membranes expressing the human cloned receptors. Moreover, their recep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2002-04, Vol.45 (8), p.1633-1643
Hauptverfasser: Quaglia, Wilma, Pigini, Maria, Piergentili, Alessandro, Giannella, Mario, Gentili, Francesco, Marucci, Gabriella, Carrieri, Antonio, Carotti, Angelo, Poggesi, Elena, Leonardi, Amedeo, Melchiorre, Carlo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1643
container_issue 8
container_start_page 1633
container_title Journal of medicinal chemistry
container_volume 45
creator Quaglia, Wilma
Pigini, Maria
Piergentili, Alessandro
Giannella, Mario
Gentili, Francesco
Marucci, Gabriella
Carrieri, Antonio
Carotti, Angelo
Poggesi, Elena
Leonardi, Amedeo
Melchiorre, Carlo
description WB4101 (1)-related compounds 5-10 were synthesized, and their biological profile at alpha(1)-adrenoreceptor (AR) subtypes and 5-HT(1A) serotoninergic receptors was assessed by binding assays in Chinese hamster ovary and HeLa cell membranes expressing the human cloned receptors. Moreover, their receptor selectivity was further determined in functional experiments in isolated rat prostate (alpha(1A)), vas deferens (alpha(1A)), aorta (alpha(1D)), and spleen (alpha(1B)). In functional assays, compound 5 was the most potent at alpha(1D)-ARs with a reversed selectivity profile (alpha(1D) > alpha(1A) > alpha(1B)) relative to both prototype 1 and phendioxan (2) (alpha(1A) > alpha(1D) > alpha(1B)), whereas compound 8, bearing a carbonyl moiety at position 1, was the most potent at alpha(1A)-ARs with a selectivity profile similar to that of prototypes. The least potent of the series was the trans isomer 6, suggesting that optimum alpha(1)-AR blocking activity in this series is associated with a cis relationship between the 2-side chain and the 4-phenyl ring rather than a trans relationship as previously observed for the 2-side chain and the 3-phenyl ring in 2 and related compounds. Binding affinity results were not in complete agreement with the selectivity profiles deriving from functional experiments. Although a firm explanation was not available, neutral and negative antagonism and receptor dimerization were considered as two possibilities to account for the difference between binding and functional affinities. Finally, compound 5 was selected for a modeling study in comparison with 1, mephendioxan (3), and open phendioxan (4) to achieve information on the physicochemical interactions that account for its high affinity toward alpha(1d/D)-ARs.
doi_str_mv 10.1021/jm011066n
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71565917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71565917</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-707060c941325c8733ce6d7b9fe678914cff3da823783f33f7d5866473a56d4d3</originalsourceid><addsrcrecordid>eNo1kMtKxDAYhbNQvIwufAHJShTMmL9pk3YpgzcQXKjrIZP8dTq0SUxScXwRX9dBndWBw8fH4RByAnwKvICr1cABuJRuhxxwXhSskIXYJ4cprTjnAgqxR_YBGgES1AH5fs5xNHmMyLTJ3UeX1zRir3PnXVp2IdHOUbgs2QLdl7ed_9SO_QJoqfFD8KOzaUrVlD5jj1uFb2nJwhLdujfL6AftqHa6928jJtr6SHUflvocLpi2EZ2PaDDkTZ_GRV4HTEdkt9V9wuP_nJDX25uX2T17fLp7mF0_sgCiyUxxxSU3TQmiqEythDAorVo0LUpVN1CathVW14VQtWiFaJWtailLJXQlbWnFhJz9eUP075txeT50yWDfa4d-THMFlawaUBvw9B8cFwPaeYjdoON6vr1S_AD1f3Vu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71565917</pqid></control><display><type>article</type><title>Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes</title><source>ACS Publications</source><source>MEDLINE</source><creator>Quaglia, Wilma ; Pigini, Maria ; Piergentili, Alessandro ; Giannella, Mario ; Gentili, Francesco ; Marucci, Gabriella ; Carrieri, Antonio ; Carotti, Angelo ; Poggesi, Elena ; Leonardi, Amedeo ; Melchiorre, Carlo</creator><creatorcontrib>Quaglia, Wilma ; Pigini, Maria ; Piergentili, Alessandro ; Giannella, Mario ; Gentili, Francesco ; Marucci, Gabriella ; Carrieri, Antonio ; Carotti, Angelo ; Poggesi, Elena ; Leonardi, Amedeo ; Melchiorre, Carlo</creatorcontrib><description>WB4101 (1)-related compounds 5-10 were synthesized, and their biological profile at alpha(1)-adrenoreceptor (AR) subtypes and 5-HT(1A) serotoninergic receptors was assessed by binding assays in Chinese hamster ovary and HeLa cell membranes expressing the human cloned receptors. Moreover, their receptor selectivity was further determined in functional experiments in isolated rat prostate (alpha(1A)), vas deferens (alpha(1A)), aorta (alpha(1D)), and spleen (alpha(1B)). In functional assays, compound 5 was the most potent at alpha(1D)-ARs with a reversed selectivity profile (alpha(1D) &gt; alpha(1A) &gt; alpha(1B)) relative to both prototype 1 and phendioxan (2) (alpha(1A) &gt; alpha(1D) &gt; alpha(1B)), whereas compound 8, bearing a carbonyl moiety at position 1, was the most potent at alpha(1A)-ARs with a selectivity profile similar to that of prototypes. The least potent of the series was the trans isomer 6, suggesting that optimum alpha(1)-AR blocking activity in this series is associated with a cis relationship between the 2-side chain and the 4-phenyl ring rather than a trans relationship as previously observed for the 2-side chain and the 3-phenyl ring in 2 and related compounds. Binding affinity results were not in complete agreement with the selectivity profiles deriving from functional experiments. Although a firm explanation was not available, neutral and negative antagonism and receptor dimerization were considered as two possibilities to account for the difference between binding and functional affinities. Finally, compound 5 was selected for a modeling study in comparison with 1, mephendioxan (3), and open phendioxan (4) to achieve information on the physicochemical interactions that account for its high affinity toward alpha(1d/D)-ARs.</description><identifier>ISSN: 0022-2623</identifier><identifier>DOI: 10.1021/jm011066n</identifier><identifier>PMID: 11931617</identifier><language>eng</language><publisher>United States</publisher><subject>Adrenergic alpha-Antagonists - chemical synthesis ; Adrenergic alpha-Antagonists - chemistry ; Adrenergic alpha-Antagonists - pharmacology ; Animals ; Aorta, Thoracic - drug effects ; Aorta, Thoracic - physiology ; CHO Cells ; Chromans - chemical synthesis ; Chromans - chemistry ; Chromans - pharmacology ; Cricetinae ; Dioxanes - chemical synthesis ; Dioxanes - chemistry ; Dioxanes - pharmacology ; HeLa Cells ; Humans ; In Vitro Techniques ; Male ; Models, Molecular ; Muscle Contraction - drug effects ; Muscle, Smooth - drug effects ; Muscle, Smooth - physiology ; Prostate - drug effects ; Prostate - physiology ; Radioligand Assay ; Rats ; Rats, Wistar ; Receptors, Adrenergic, alpha-1 - drug effects ; Receptors, Adrenergic, alpha-1 - metabolism ; Receptors, Serotonin - metabolism ; Receptors, Serotonin, 5-HT1 ; Spleen - drug effects ; Spleen - physiology ; Structure-Activity Relationship ; Vas Deferens - drug effects ; Vas Deferens - physiology</subject><ispartof>Journal of medicinal chemistry, 2002-04, Vol.45 (8), p.1633-1643</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11931617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quaglia, Wilma</creatorcontrib><creatorcontrib>Pigini, Maria</creatorcontrib><creatorcontrib>Piergentili, Alessandro</creatorcontrib><creatorcontrib>Giannella, Mario</creatorcontrib><creatorcontrib>Gentili, Francesco</creatorcontrib><creatorcontrib>Marucci, Gabriella</creatorcontrib><creatorcontrib>Carrieri, Antonio</creatorcontrib><creatorcontrib>Carotti, Angelo</creatorcontrib><creatorcontrib>Poggesi, Elena</creatorcontrib><creatorcontrib>Leonardi, Amedeo</creatorcontrib><creatorcontrib>Melchiorre, Carlo</creatorcontrib><title>Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes</title><title>Journal of medicinal chemistry</title><addtitle>J Med Chem</addtitle><description>WB4101 (1)-related compounds 5-10 were synthesized, and their biological profile at alpha(1)-adrenoreceptor (AR) subtypes and 5-HT(1A) serotoninergic receptors was assessed by binding assays in Chinese hamster ovary and HeLa cell membranes expressing the human cloned receptors. Moreover, their receptor selectivity was further determined in functional experiments in isolated rat prostate (alpha(1A)), vas deferens (alpha(1A)), aorta (alpha(1D)), and spleen (alpha(1B)). In functional assays, compound 5 was the most potent at alpha(1D)-ARs with a reversed selectivity profile (alpha(1D) &gt; alpha(1A) &gt; alpha(1B)) relative to both prototype 1 and phendioxan (2) (alpha(1A) &gt; alpha(1D) &gt; alpha(1B)), whereas compound 8, bearing a carbonyl moiety at position 1, was the most potent at alpha(1A)-ARs with a selectivity profile similar to that of prototypes. The least potent of the series was the trans isomer 6, suggesting that optimum alpha(1)-AR blocking activity in this series is associated with a cis relationship between the 2-side chain and the 4-phenyl ring rather than a trans relationship as previously observed for the 2-side chain and the 3-phenyl ring in 2 and related compounds. Binding affinity results were not in complete agreement with the selectivity profiles deriving from functional experiments. Although a firm explanation was not available, neutral and negative antagonism and receptor dimerization were considered as two possibilities to account for the difference between binding and functional affinities. Finally, compound 5 was selected for a modeling study in comparison with 1, mephendioxan (3), and open phendioxan (4) to achieve information on the physicochemical interactions that account for its high affinity toward alpha(1d/D)-ARs.</description><subject>Adrenergic alpha-Antagonists - chemical synthesis</subject><subject>Adrenergic alpha-Antagonists - chemistry</subject><subject>Adrenergic alpha-Antagonists - pharmacology</subject><subject>Animals</subject><subject>Aorta, Thoracic - drug effects</subject><subject>Aorta, Thoracic - physiology</subject><subject>CHO Cells</subject><subject>Chromans - chemical synthesis</subject><subject>Chromans - chemistry</subject><subject>Chromans - pharmacology</subject><subject>Cricetinae</subject><subject>Dioxanes - chemical synthesis</subject><subject>Dioxanes - chemistry</subject><subject>Dioxanes - pharmacology</subject><subject>HeLa Cells</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Models, Molecular</subject><subject>Muscle Contraction - drug effects</subject><subject>Muscle, Smooth - drug effects</subject><subject>Muscle, Smooth - physiology</subject><subject>Prostate - drug effects</subject><subject>Prostate - physiology</subject><subject>Radioligand Assay</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Adrenergic, alpha-1 - drug effects</subject><subject>Receptors, Adrenergic, alpha-1 - metabolism</subject><subject>Receptors, Serotonin - metabolism</subject><subject>Receptors, Serotonin, 5-HT1</subject><subject>Spleen - drug effects</subject><subject>Spleen - physiology</subject><subject>Structure-Activity Relationship</subject><subject>Vas Deferens - drug effects</subject><subject>Vas Deferens - physiology</subject><issn>0022-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtKxDAYhbNQvIwufAHJShTMmL9pk3YpgzcQXKjrIZP8dTq0SUxScXwRX9dBndWBw8fH4RByAnwKvICr1cABuJRuhxxwXhSskIXYJ4cprTjnAgqxR_YBGgES1AH5fs5xNHmMyLTJ3UeX1zRir3PnXVp2IdHOUbgs2QLdl7ed_9SO_QJoqfFD8KOzaUrVlD5jj1uFb2nJwhLdujfL6AftqHa6928jJtr6SHUflvocLpi2EZ2PaDDkTZ_GRV4HTEdkt9V9wuP_nJDX25uX2T17fLp7mF0_sgCiyUxxxSU3TQmiqEythDAorVo0LUpVN1CathVW14VQtWiFaJWtailLJXQlbWnFhJz9eUP075txeT50yWDfa4d-THMFlawaUBvw9B8cFwPaeYjdoON6vr1S_AD1f3Vu</recordid><startdate>20020411</startdate><enddate>20020411</enddate><creator>Quaglia, Wilma</creator><creator>Pigini, Maria</creator><creator>Piergentili, Alessandro</creator><creator>Giannella, Mario</creator><creator>Gentili, Francesco</creator><creator>Marucci, Gabriella</creator><creator>Carrieri, Antonio</creator><creator>Carotti, Angelo</creator><creator>Poggesi, Elena</creator><creator>Leonardi, Amedeo</creator><creator>Melchiorre, Carlo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20020411</creationdate><title>Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes</title><author>Quaglia, Wilma ; Pigini, Maria ; Piergentili, Alessandro ; Giannella, Mario ; Gentili, Francesco ; Marucci, Gabriella ; Carrieri, Antonio ; Carotti, Angelo ; Poggesi, Elena ; Leonardi, Amedeo ; Melchiorre, Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-707060c941325c8733ce6d7b9fe678914cff3da823783f33f7d5866473a56d4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adrenergic alpha-Antagonists - chemical synthesis</topic><topic>Adrenergic alpha-Antagonists - chemistry</topic><topic>Adrenergic alpha-Antagonists - pharmacology</topic><topic>Animals</topic><topic>Aorta, Thoracic - drug effects</topic><topic>Aorta, Thoracic - physiology</topic><topic>CHO Cells</topic><topic>Chromans - chemical synthesis</topic><topic>Chromans - chemistry</topic><topic>Chromans - pharmacology</topic><topic>Cricetinae</topic><topic>Dioxanes - chemical synthesis</topic><topic>Dioxanes - chemistry</topic><topic>Dioxanes - pharmacology</topic><topic>HeLa Cells</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Models, Molecular</topic><topic>Muscle Contraction - drug effects</topic><topic>Muscle, Smooth - drug effects</topic><topic>Muscle, Smooth - physiology</topic><topic>Prostate - drug effects</topic><topic>Prostate - physiology</topic><topic>Radioligand Assay</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Adrenergic, alpha-1 - drug effects</topic><topic>Receptors, Adrenergic, alpha-1 - metabolism</topic><topic>Receptors, Serotonin - metabolism</topic><topic>Receptors, Serotonin, 5-HT1</topic><topic>Spleen - drug effects</topic><topic>Spleen - physiology</topic><topic>Structure-Activity Relationship</topic><topic>Vas Deferens - drug effects</topic><topic>Vas Deferens - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quaglia, Wilma</creatorcontrib><creatorcontrib>Pigini, Maria</creatorcontrib><creatorcontrib>Piergentili, Alessandro</creatorcontrib><creatorcontrib>Giannella, Mario</creatorcontrib><creatorcontrib>Gentili, Francesco</creatorcontrib><creatorcontrib>Marucci, Gabriella</creatorcontrib><creatorcontrib>Carrieri, Antonio</creatorcontrib><creatorcontrib>Carotti, Angelo</creatorcontrib><creatorcontrib>Poggesi, Elena</creatorcontrib><creatorcontrib>Leonardi, Amedeo</creatorcontrib><creatorcontrib>Melchiorre, Carlo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quaglia, Wilma</au><au>Pigini, Maria</au><au>Piergentili, Alessandro</au><au>Giannella, Mario</au><au>Gentili, Francesco</au><au>Marucci, Gabriella</au><au>Carrieri, Antonio</au><au>Carotti, Angelo</au><au>Poggesi, Elena</au><au>Leonardi, Amedeo</au><au>Melchiorre, Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J Med Chem</addtitle><date>2002-04-11</date><risdate>2002</risdate><volume>45</volume><issue>8</issue><spage>1633</spage><epage>1643</epage><pages>1633-1643</pages><issn>0022-2623</issn><abstract>WB4101 (1)-related compounds 5-10 were synthesized, and their biological profile at alpha(1)-adrenoreceptor (AR) subtypes and 5-HT(1A) serotoninergic receptors was assessed by binding assays in Chinese hamster ovary and HeLa cell membranes expressing the human cloned receptors. Moreover, their receptor selectivity was further determined in functional experiments in isolated rat prostate (alpha(1A)), vas deferens (alpha(1A)), aorta (alpha(1D)), and spleen (alpha(1B)). In functional assays, compound 5 was the most potent at alpha(1D)-ARs with a reversed selectivity profile (alpha(1D) &gt; alpha(1A) &gt; alpha(1B)) relative to both prototype 1 and phendioxan (2) (alpha(1A) &gt; alpha(1D) &gt; alpha(1B)), whereas compound 8, bearing a carbonyl moiety at position 1, was the most potent at alpha(1A)-ARs with a selectivity profile similar to that of prototypes. The least potent of the series was the trans isomer 6, suggesting that optimum alpha(1)-AR blocking activity in this series is associated with a cis relationship between the 2-side chain and the 4-phenyl ring rather than a trans relationship as previously observed for the 2-side chain and the 3-phenyl ring in 2 and related compounds. Binding affinity results were not in complete agreement with the selectivity profiles deriving from functional experiments. Although a firm explanation was not available, neutral and negative antagonism and receptor dimerization were considered as two possibilities to account for the difference between binding and functional affinities. Finally, compound 5 was selected for a modeling study in comparison with 1, mephendioxan (3), and open phendioxan (4) to achieve information on the physicochemical interactions that account for its high affinity toward alpha(1d/D)-ARs.</abstract><cop>United States</cop><pmid>11931617</pmid><doi>10.1021/jm011066n</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2002-04, Vol.45 (8), p.1633-1643
issn 0022-2623
language eng
recordid cdi_proquest_miscellaneous_71565917
source ACS Publications; MEDLINE
subjects Adrenergic alpha-Antagonists - chemical synthesis
Adrenergic alpha-Antagonists - chemistry
Adrenergic alpha-Antagonists - pharmacology
Animals
Aorta, Thoracic - drug effects
Aorta, Thoracic - physiology
CHO Cells
Chromans - chemical synthesis
Chromans - chemistry
Chromans - pharmacology
Cricetinae
Dioxanes - chemical synthesis
Dioxanes - chemistry
Dioxanes - pharmacology
HeLa Cells
Humans
In Vitro Techniques
Male
Models, Molecular
Muscle Contraction - drug effects
Muscle, Smooth - drug effects
Muscle, Smooth - physiology
Prostate - drug effects
Prostate - physiology
Radioligand Assay
Rats
Rats, Wistar
Receptors, Adrenergic, alpha-1 - drug effects
Receptors, Adrenergic, alpha-1 - metabolism
Receptors, Serotonin - metabolism
Receptors, Serotonin, 5-HT1
Spleen - drug effects
Spleen - physiology
Structure-Activity Relationship
Vas Deferens - drug effects
Vas Deferens - physiology
title Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T13%3A05%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure-activity%20relationships%20in%201,4-benzodioxan-related%20compounds.%207.%20Selectivity%20of%204-phenylchroman%20analogues%20for%20alpha(1)-adrenoreceptor%20subtypes&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Quaglia,%20Wilma&rft.date=2002-04-11&rft.volume=45&rft.issue=8&rft.spage=1633&rft.epage=1643&rft.pages=1633-1643&rft.issn=0022-2623&rft_id=info:doi/10.1021/jm011066n&rft_dat=%3Cproquest_pubme%3E71565917%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71565917&rft_id=info:pmid/11931617&rfr_iscdi=true